'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Dr Lal Pathlabs has increased 9.80% to Rs 660.2 crore. Operating profit margin has jumped from 29.57% to 30.67%, leading to 13.89% rise in operating profit to Rs 202.50 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 20.36% to 19.28%. Employee cost increased from 17.53% to 18.78%. Other expenses fell from 32.55% to 31.26%. Selling and administration expenses rose from 14.17% to 14.19%.
Other income rose 20.99% to Rs 21.9 crore. PBIDT rose 14.55% to Rs 224.4 crore. Provision for interest fell 23.08% to Rs 6 crore. Loan funds declined from Rs 299.20 crore as of 30 September 2023 to Rs 198.50 crore as of 30 September 2024. Inventories rose to Rs 46.80 crore as o...
Pleaselogin & subscribe to view the full report.
More Reports
-
Muted premium collection growth
-
(31-Oct-2024)
Dabur India
-
Sustains strong performance
-
Net up 31% on good operating show
|